Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft Model
- 6 July 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (1) , 67-74
- https://doi.org/10.1161/01.cir.100.1.67
Abstract
Background—Chronic graft vascular disease (CGVD) in cardiac allografts has been defined as a slowly evolving vasculopathy unresponsive to conventional immunosuppression. We compared 4 rodent models...Keywords
This publication has 17 references indexed in Scilit:
- IRREVERSIBLE CHRONIC VASCULAR REJECTION OCCURS ONLY AFTER DEVELOPMENT OF ADVANCED ALLOGRAFT VASCULOPATHYTransplantation, 1997
- IN VIVO STUDIES OF THE MAINTENANCE OF PERIPHERAL TRANSPLANT TOLERANCE AFTER CYCLOSPORINETransplantation, 1995
- TREATMENT WITH RAPAMYCIN AND MYCOPHENOLIC ACID REDUCES ARTERIAL INTIMAL THICKENING PRODUCED BY MECHANICAL INJURY AND ALLOWS ENDOTHELIAL REPLACEMENTTransplantation, 1995
- EFFECTS OF RAPAMYCIN ON GROWTH FACTOR-STIMULATED VASCULAR SMOOTH MUSCLE CELL DNA SYNTHESIS INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR AND PLATELET-DERIVED GROWTH FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506Transplantation, 1995
- CARDIAC ALLOGRAFT ATHEROSCLEROSIS IN THE RATTransplantation, 1994
- Chronic graft rejectionCurrent Opinion in Immunology, 1994
- LATE CYCLOSPORINE TREATMENT AMELIORATES ESTABLISHED CORONARY GRAFT DISEASE IN RAT ALLOGRAFTSTransplantation, 1993
- Chronic Rejection in Experimental Cardiac Transplantation: Studies in the Lewis‐F344 ModelImmunological Reviews, 1993
- Effects of cyclosporin, FK506, and rapamycin on graft-vessel diseaseThe Lancet, 1991
- CARDIAC TRANSPLANTATION IN THE RATTransplantation, 1989